Market Chameleon (Fri, 19-Dec 4:51 AM ET)
From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape
Globe Newswire (Fri, 19-Dec 9:48 AM ET)
Globe Newswire (Fri, 19-Dec 7:00 AM ET)
Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on December 1
Globe Newswire (Wed, 26-Nov 8:00 AM ET)
Globe Newswire (Wed, 19-Nov 8:13 AM ET)
ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19
Globe Newswire (Tue, 18-Nov 8:00 AM ET)
ProPhase Labs Urges Shareholders to Vote by November 23 on Proxy Proposals
Globe Newswire (Mon, 17-Nov 8:00 AM ET)
Globe Newswire (Wed, 29-Oct 8:30 AM ET)
ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts
Globe Newswire (Tue, 28-Oct 8:00 AM ET)
ProPhase Labs to Present at the 2025 ThinkEquity Conference
Globe Newswire (Fri, 24-Oct 8:00 AM ET)
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.
Prophase Labs trades on the NASDAQ stock market under the symbol PRPH.
As of December 29, 2025, PRPH stock price declined to $0.51 with 47,876 million shares trading.
PRPH has a beta of 4.38, meaning it tends to be more sensitive to market movements. PRPH has a correlation of 0.19 to the broad based SPY ETF.
PRPH has a market cap of $2.14 million. This is considered a Sub-Micro Cap stock.
Last quarter Prophase Labs reported $883,000 in Revenue and -$1.60 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.50.
In the last 3 years, PRPH traded as high as $99.41 and as low as $.50.
The top ETF exchange traded funds that PRPH belongs to (by Net Assets): VXF.
PRPH has underperformed the market in the last year with a price return of -91.9% while the SPY ETF gained +15.7%. PRPH has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -88.5% and -55.6%, respectively, while the SPY returned +4.3% and +1.3%, respectively.
PRPH support price is $.44 and resistance is $.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRPH shares will trade within this expected range on the day.